Data on the investigative, temporary gut liner, EndoBarrier, showed improvement in weight, A1c, fatty liver, and need for insulin, and the effect persisted for up to 2 years after its removal.
Shares in Zealand Pharma soared 34% on Monday after an experimental weight-loss drug it is developing with Boehringer Ingelheim yielded what they called "groundbreaking".
Investigators from the ongoing MAESTRO-NASH trial provided more evidence that resmetirom may be a viable option in a disease state currently without any approved treatments.
Sagimet Biosciences said on Monday its experimental drug to treat a fatty liver disease significantly reduced the symptoms in a mid-stage study, sending the drug maker's.